ArisGlobal unveils its NavaX Agents Suite, an innovative set of autonomous, domain-trained AI agents designed to transform operational workflows and regulatory compliance within the life sciences industry, starting with award-winning MedDRA coding technology.
ArisGlobal, a technology company specialising in life sciences, has announced the launch of its NavaX Agents Suite, an expansion of its AI capabilities within the LifeSphere® Unify platform. According to the compa...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
ny, the suite is designed to integrate multiple specialised AI agents, each tasked with specific functions, coordinated by an overarching “NavaX Super Agent” that autonomously manages multi-step processes. The initiative reflects ArisGlobal’s stated commitment to advancing agentic AI—autonomous, domain-trained systems that aim to reason, learn, and collaborate to improve operational efficiency and compliance in life sciences workflows.
The first component of this suite, the MedDRA Coding Agent, has already been released. ArisGlobal claims this agent revolutionises medical coding by emulating human cognitive skills in contextually interpreting clinical data, thereby moving beyond traditional rule-based systems. This technology reportedly enhances accuracy, efficiency, and auditability in medical coding tasks, which are critical to pharmacovigilance and regulatory compliance. The MedDRA Coding Agent has been recognised with Frost & Sullivan’s 2025 Global New Product Innovation Award, signalling industry validation for its innovative application of AI in pharmacovigilance.
ArisGlobal outlines future expansions of the NavaX suite scheduled for release between 2025 and 2026. These include agents specialised in areas such as signal detection and assessment, distribution, and regulatory intelligence. The company emphasises the seamless integration of these agents within a connected ecosystem that spans safety, regulatory affairs, quality assurance, and medical affairs across a product’s lifecycle.
The firm positions the NavaX Agents as a unique approach to life sciences AI, differentiating them from stand-alone or third-party tools by integrating deeply with existing platform capabilities. Jason Bryant, SVP of Product Management – AI at ArisGlobal, stated that their AI systems are built to “think, act, and evolve alongside users,” aiming to deliver tangible returns through improved efficiency and insight generation. CEO Aman Wasan described the NavaX Agents as intelligent collaborators designed to accelerate processes and elevate quality across the product lifecycle.
Independent reports on the MedDRA Coding Agent highlight significant efficiency improvements, with some claims noting up to 80% gains in coding automation, alongside reductions in reviewer workload and noise/errors without compromising accuracy. The agent reportedly supports multiple languages and complies with global regulatory standards, enabling integration with existing safety databases and systems. Its cognitive capabilities include dynamically selecting tools, learning continuously from user feedback, and collaborating with reviewers when necessary—emulating the nuanced judgment of experienced professionals.
While the company’s narrative focuses on the transformative potential of these agentic AI systems, external perspectives underline the broader industry trend toward increasing automation and intelligent analytics in pharmacovigilance and regulatory processes. However, the real-world impact and adoption of these technologies will likely depend on their integration ease, regulatory acceptance, and ongoing effectiveness amidst evolving medical terminologies and compliance requirements.
ArisGlobal’s launch of the NavaX Agents Suite is positioned as part of a broader digital transformation strategy for life sciences organisations, aiming to expedite R&D, ensure regulatory compliance, and ultimately accelerate the delivery of safer therapies to patients. The emphasis on agentic AI reflects a growing interest in AI systems capable of autonomous reasoning and task execution within complex, domain-specific environments.
In summary, ArisGlobal claims that the NavaX Agents represent a new paradigm in life sciences AI, combining domain expertise, trusted data, and ethical AI principles to enhance productivity and insight generation across multiple operational areas. The MedDRA Coding Agent’s industry recognition supports this claim, though broader implementation and long-term outcomes remain to be fully observed in the sector.
Source: Noah Wire Services
